TFII.TO -1.7C -0.17MU -19.63CRWD 5.69PANW 4.39SNOW 16.89V 3.35MAL.TO -0.14
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.21
+0.20 (0.78%)
as of Aug 3, 2026, 1:30:21 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 2, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing challenges following its pandemic-driven peak during which it surged due to COVID-19 vaccine sales. Experts have pointed out a lack of earnings momentum and concerns over a patent cliff, as key drugs have come off patent and the company needs to innovate to develop new blockbuster drugs. Despite these challenges, many analysts emphasize the attractive dividend yield, which remains around 6-8%. The company is pivoting towards growth areas such as obesity and oncology, and while there's a general belief that PFE is under pressure, patience from investors could yield positive results. Several insights indicate that while it may not attract immediate growth, the company’s efforts in acquisitions and drug development could eventually pay off, given time.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
TOP PICK

Pfizer Inc(PFE)

Feb 01, 2007
This is a balance sheet story. They have a huge balance sheet that they can’t do anything with. Volatility in the stock price has fallen. New management wants to fire 10,000 people, etc. and it sounds like he wants to reduce the balance sheet. A restructuring story. 5% dividend. His current model price is $40, a 51% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.62

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jan 25, 2007
Drug companies have been struggling under generic competition as well as a difficult regulatory environment. Looks like compelling value here but would be more comfortable at $24.
Photo of John O'Connell, CFAJohn O'Connell, CFAUnlock Rating
$26.36

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 24, 2007
Hard one to play because it's in the drug space and there is a lot of litigation happening. From a trading perspective, this is a dangerous one to play.
Photo of John ManleyJohn Manley
No
Unlock Rating
$26.82

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Jan 22, 2007
Big pharmaceutical pipelines product lines are getting squeezed and they have to cut costs. Relatively cheap, but the growth rate is not as good as it was.
Photo of John ZechnerJohn ZechnerUnlock Rating
$26.95

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 15, 2007
Like many of the pharmaceuticals, it is a company in transition. Won't go up aggressively, but it pays a decent yield. Historically, these companies have done well and they throw off a lot of free cash flow. New management is expected to cut costs and the company is buying back stock. Good balance sheet. Cheap.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$26.64

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jan 09, 2007
They have a great balance sheet and a yield over 4%. If you own, he would stick with it at this time.
Photo of Charles LannonCharles Lannon
No
Unlock Rating
$26.17

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 04, 2007
Had a number of one time issues that have been happening which has made it a bad investment for the last 5 years. Probably near its bottom now. Would consider it in the $21 area.
Photo of Alex RuusAlex Ruus
No
Unlock Rating
$26.38

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jan 03, 2007
If you want to stay in the pharmaceutical space, he would prefer Eli Lilly (LLY-N).
Photo of Steve MacMillanSteve MacMillan
No
Unlock Rating
$26.29

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 21, 2006
His model price is $39. That’s a 49% positive differential. Looking out 1 year with their earnings, it’s a 15% return, plus the dividend of 4.4% gives a 20% implied rate of return.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.07

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 18, 2006
Pulled a replacement for Lipitor because of poor tests. Wasn’t going to contribute until 2010. Stock dropped. Near its all time low. Pristine balance sheet. Oversold.
Photo of David Taylor, MBA, CFADavid Taylor, MBA, CFA
Owned
Unlock Rating
$25.83

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 12, 2006
Likes the pharmaceutical industry, as it is undervalued. In the long term, it will come back. They will have to cut costs dramatically over the next several years. Cheap. Pays a 4% yield. Defensive. Won’t have dramatic moves.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$25.17

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 05, 2006
One for over 1, 2 and 3 years. Lost their major new blockbuster drug, but it wasn’t due on the market until Lipitor came off patent, 4 years out. Has $38 billion in cash and generates about $14 billion cash a year. Dividend yield of 3.9% and sees it going up a lot.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$24.82

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 05, 2006
What happened to their drug yesterday will probably mean the stock will stay down for awhile.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$24.82

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Dec 04, 2006
(A Top Pick Aug 3/06. Down 4.2%.) Have sold their consumer products division and have a tremendous amount of cash coming in, giving them a very strong balance sheet. A Hold.
Photo of Ross HealyRoss Healy
Owned
Unlock Rating
$24.90

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 30, 2006
Pharmaceutical and health care area has been very difficult. Has done better in the last 6 months. A cheap stock.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$27.49

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
Showing 586 to 600 of 885 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EOG -2.68$146.01
SLB -1.22$48.37
SHEL -0.8$91.18
AAPL -2.76$306.15
AMZN 12.495$284.075

Today's Top Picks

TFII.TO -1.7$13.38
C -0.17$132.28
MU -19.63$803.4
CRWD 5.69$196.55
PANW 4.39$336.22

Popular Articles

Latest Sell Signals

AAPL -2.76$306.15
AAPL -2.76$306.15
AAPL -2.76$306.15
T.TO -1.7$13.38
CCA.TO -1.1$59.1

Most Recent Experts

Amy Raskin, CIO, Chevy Chase Trust

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like